Akero Therapeutics (STU:0K4) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Days Payable?

Akero Therapeutics's average Accounts Payable for the three months ended in Dec. 2024 was €15.67 Mil. Akero Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was €0.00 Mil.

The historical rank and industry rank for Akero Therapeutics's Days Payable or its related term are showing as below:

STU:0K4's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 118.245
* Ranked among companies with meaningful Days Payable only.

Akero Therapeutics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Akero Therapeutics Days Payable Historical Data

The historical data trend for Akero Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics Days Payable Chart

Akero Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Akero Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Akero Therapeutics's Days Payable

For the Biotechnology subindustry, Akero Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akero Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Akero Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Akero Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (6.454	+	8.621)	/	2 )	/	0	*	365
=	7.5375					/	0	*	365
=	N/A

Akero Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (22.726	+	8.621)	/	2 )	/	0	*	365 / 4
=	15.6735					/	0	*	365 / 4
=	N/A

Akero Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AKRO:USA 0K4:Germany

Address

601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.akerotx.com

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines